X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA NOVARTIS ELDER PHARMA/
NOVARTIS
 
P/E (TTM) x -0.2 361.2 - View Chart
P/BV x 0.1 17.8 0.6% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 ELDER PHARMA   NOVARTIS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
NOVARTIS
Mar-16
ELDER PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs380982 38.7%   
Low Rs188556 33.8%   
Sales per share (Unadj.) Rs491.2252.9 194.2%  
Earnings per share (Unadj.) Rs-3.262.1 -5.1%  
Cash flow per share (Unadj.) Rs14.463.3 22.8%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs376.5363.6 103.5%  
Shares outstanding (eoy) m20.5431.96 64.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.0 19.0%   
Avg P/E ratio x-89.312.4 -721.2%  
P/CF ratio (eoy) x19.712.2 162.2%  
Price / Book Value ratio x0.82.1 35.7%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m5,83324,580 23.7%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,1791,801 121.0%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m10,0898,083 124.8%  
Other income Rs m257829 30.9%   
Total revenues Rs m10,3468,913 116.1%   
Gross profit Rs m-792234 -338.1%  
Depreciation Rs m36137 984.5%   
Interest Rs m2,7562 153,127.8%   
Profit before tax Rs m-3,6531,025 -356.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m3,7131,696 218.9%   
Tax Rs m125752 16.6%   
Profit after tax Rs m-651,986 -3.3%  
Gross profit margin %-7.82.9 -270.9%  
Effective tax rate %-3.473.4 -4.7%   
Net profit margin %-0.624.6 -2.6%  
BALANCE SHEET DATA
Current assets Rs m9,24012,678 72.9%   
Current liabilities Rs m9,9982,433 410.9%   
Net working cap to sales %-7.5126.7 -5.9%  
Current ratio x0.95.2 17.7%  
Inventory Days Days4633 141.6%  
Debtors Days Days6022 266.5%  
Net fixed assets Rs m10,12469 14,629.6%   
Share capital Rs m206160 128.7%   
"Free" reserves Rs m5,58211,460 48.7%   
Net worth Rs m7,73411,621 66.5%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88214,400 158.9%  
Interest coverage x-0.3570.5 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 78.5%   
Return on assets %11.813.8 85.2%  
Return on equity %-0.817.1 -4.9%  
Return on capital %22.323.6 94.6%  
Exports to sales %3.00.7 408.0%   
Imports to sales %0.418.6 2.3%   
Exports (fob) Rs m30760 509.3%   
Imports (cif) Rs m431,503 2.9%   
Fx inflow Rs m307186 164.6%   
Fx outflow Rs m1251,821 6.9%   
Net fx Rs m181-1,635 -11.1%   
CASH FLOW
From Operations Rs m11,7542,531 464.4%  
From Investments Rs m-561-8,270 6.8%  
From Financial Activity Rs m-6,762-386 1,753.1%  
Net Cashflow Rs m4,432-6,125 -72.4%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 16.8 1.6 1,050.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 21.5 167.9%  
Shareholders   16,479 41,647 39.6%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - GLENMARK PHARMA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS